315 related articles for article (PubMed ID: 15818441)
21. [Fabry disease: clinic and enzymatic diagnosis of homozygous and heterozygous. New therapeutic prospects].
Peces R; Olea T
Nefrologia; 2002; 22(6):540-6. PubMed ID: 12516287
[TBL] [Abstract][Full Text] [Related]
22. [Ocular findings in Fabry's disease].
Kuzman T; Juri J; Mrsić M; Jeren-Strujić B; Mandić Z; Sikić J
Acta Med Croatica; 2006; 60(2):163-6. PubMed ID: 16848212
[TBL] [Abstract][Full Text] [Related]
23. Identification of a novel mutation and prevalence study for fabry disease in Japanese dialysis patients.
Nishino T; Obata Y; Furusu A; Hirose M; Shinzato K; Hattori K; Nakamura K; Matsumoto T; Endo F; Kohno S
Ren Fail; 2012; 34(5):566-70. PubMed ID: 22563919
[TBL] [Abstract][Full Text] [Related]
24. [Fabry disease: data from four families].
Slee PH; van Boven LJ; Slee DS
Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2412-5. PubMed ID: 11145098
[TBL] [Abstract][Full Text] [Related]
25. Novel frameshift mutation in a heterozygous woman with Fabry disease and end-stage renal failure.
Van Loo A; Vanholder R; Madsen K; Praet M; Kint J; De Paepe A; Messiaen L; Lameire N; Hasholt L; Sørensen SA; Ringoir S
Am J Nephrol; 1996; 16(4):352-7. PubMed ID: 8739292
[TBL] [Abstract][Full Text] [Related]
26. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
Breunig F; Wanner C
J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
[TBL] [Abstract][Full Text] [Related]
27. Novel α-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease.
Duro G; Musumeci MB; Colomba P; Zizzo C; Albeggiani G; Mastromarino V; Volpe M; Autore C
Gene; 2014 Feb; 535(2):365-9. PubMed ID: 24140492
[TBL] [Abstract][Full Text] [Related]
28. Fabry disease.
Tarabuso AL
Skinmed; 2011; 9(3):173-7. PubMed ID: 21675497
[TBL] [Abstract][Full Text] [Related]
29. Multiple parapelvic cysts in Fabry disease.
Azancot MA; Vila J; Domínguez C; Serres X; Espinel E
Nefrologia; 2016; 36(3):310-2. PubMed ID: 27061865
[TBL] [Abstract][Full Text] [Related]
30. Point mutation in the alpha-galactosidase A gene of atypical Fabry disease with only nephropathy.
Sawada K; Mizoguchi K; Hishida A; Kaneko E; Koide Y; Nishimura K; Kimura M
Clin Nephrol; 1996 May; 45(5):289-94. PubMed ID: 8738659
[TBL] [Abstract][Full Text] [Related]
31. Remarkable variability in renal disease in a large Slovenian family with Fabry disease.
Verovnik F; Benko D; Vujkovac B; Linthorst GE
Eur J Hum Genet; 2004 Aug; 12(8):678-81. PubMed ID: 15162124
[TBL] [Abstract][Full Text] [Related]
32. A novel alpha-galactosidase a mutant (M42L) identified in a renal variant of Fabry disease.
Rosenthal D; Lien YH; Lager D; Lai LW; Shang S; Leung N; Fervenza FC
Am J Kidney Dis; 2004 Nov; 44(5):e85-9. PubMed ID: 15492942
[TBL] [Abstract][Full Text] [Related]
33. Control of proteinuria with increased doses of agalsidase alfa in a patient with Fabry disease with atypical genotype-phenotype expression.
Paliouras C; Aperis G; Lamprianou F; Ntetskas G; Roufas K; Alivanis P
Nefrologia; 2015; 35(6):578-81. PubMed ID: 26384850
[TBL] [Abstract][Full Text] [Related]
34. [The neurological manifestations of Fabry disease. A review].
Firsov KV; Kotov AS
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(9):98-105. PubMed ID: 27735906
[TBL] [Abstract][Full Text] [Related]
35. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.
Ortiz A; Cianciaruso B; Cizmarik M; Germain DP; Mignani R; Oliveira JP; Villalobos J; Vujkovac B; Waldek S; Wanner C; Warnock DG
Nephrol Dial Transplant; 2010 Mar; 25(3):769-75. PubMed ID: 19846394
[TBL] [Abstract][Full Text] [Related]
36. [Enzyme replacement therapy in Fabry's disease].
Alvarez L; del Pozo C; Trigueros M; Sánchez L; Albero MD; López-Menchero R; Ortega E
Nefrologia; 2005; 25(3):322-7. PubMed ID: 16053014
[TBL] [Abstract][Full Text] [Related]
37. Novel α-Galactosidase A Mutation (K391E) in a Young Woman With Severe Cardiac and Renal Manifestations of Fabry Disease.
Wakakuri H; Nakamura S; Utsumi K; Shimizu W; Yasutake M
Int Heart J; 2016 Sep; 57(5):637-9. PubMed ID: 27593536
[TBL] [Abstract][Full Text] [Related]
38. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.
Bersano A; Lanfranconi S; Valcarenghi C; Bresolin N; Micieli G; Baron P
Acta Neurol Scand; 2012 Aug; 126(2):77-97. PubMed ID: 22428782
[TBL] [Abstract][Full Text] [Related]
39. A successful approach for the detection of Fabry patients in Argentina.
Rozenfeld PA; Tarabuso A; Ebner R; Ramallo G; Fossati CA
Clin Genet; 2006 Apr; 69(4):344-8. PubMed ID: 16630168
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study.
Rolfs A; Böttcher T; Zschiesche M; Morris P; Winchester B; Bauer P; Walter U; Mix E; Löhr M; Harzer K; Strauss U; Pahnke J; Grossmann A; Benecke R
Lancet; 2005 Nov; 366(9499):1794-6. PubMed ID: 16298216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
